ConductScience.org, home

Paper36747017

Immune checkpoint inhibitor combinations-current and emerging strategies.

Walsh RJ and 2 others. Br J Cancer, 2023. Cited by 80 papers, by iCite.

Cite this record

ConductScience Library. Immune checkpoint inhibitor combinations-current and emerging strategies. Papers, record 36747017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36747017

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune checkpoint inhibitor combinations-current and emerging strategies.
PubMed
Journal
Br J Cancer
PubMed
Year
2023
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
80
iCite
Relative citation ratio, by iCite
6.75
iCite
Revised in PubMed
2024-02-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Walsh RJRobert J
2Sundar RRaghavhttps://orcid.org/0000-0001-9423-1368
3Lim JSJJoline S Jhttps://orcid.org/0000-0001-8979-8597

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immune Checkpoint InhibitorsMajor topic
ImmunotherapyMajor topic
Humans

References8

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133811048Development of Immunotherapy Combination Strategies in Cancer.Cancer Discov2021https://conductscience.org/library/papers/33811048PubMed
235978433Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.J Hematol Oncol2022https://conductscience.org/library/papers/35978433PubMed
331050707Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.Ann Oncol2019https://conductscience.org/library/papers/31050707PubMed
435507017A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.Clin Cancer Res2022https://conductscience.org/library/papers/35507017PubMed
532948597Revisiting the PD-1 pathway.Sci Adv2020https://conductscience.org/library/papers/32948597PubMed
634980128Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.Cancer Cell Int2022https://conductscience.org/library/papers/34980128PubMed
735228755Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.Nat Med2022https://conductscience.org/library/papers/35228755PubMed
833580222PD-L1 as a biomarker of response to immune-checkpoint inhibitors.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/33580222PubMed

Download CSV of references

Cited by57

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.

PMIDTitleJournalYearIn PapersSource
42958364Immune checkpoints: cross-disease insights and clinical dilemmas.Biomark Res2026https://conductscience.org/library/papers/42958364PubMed
42909707Patients' lived experiences of fractures during immune checkpoint inhibitor therapy: a qualitative study.Arch Osteoporos2026https://conductscience.org/library/papers/42909707PubMed
42823086Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death.J Immunother Cancer2026https://conductscience.org/library/papers/42823086PubMed
42716675Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes.Clin Respir J2026https://conductscience.org/library/papers/42716675PubMed
42699051NF-κB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy.iScience2026https://conductscience.org/library/papers/42699051PubMed
42621362Biohybrid Salmonella typhimurium for synergistic chemoimmunotherapy via localized chemotherapy and in situ PD-L1 blockade.Mater Today Bio2026https://conductscience.org/library/papers/42621362PubMed
42237783Immune checkpoint therapy in pediatric and adolescent lymphomas.Haematologica2026https://conductscience.org/library/papers/42237783PubMed
42006716Carbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook.Mater Today Bio2026https://conductscience.org/library/papers/42006716PubMed
41992056Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer Med2026https://conductscience.org/library/papers/41992056PubMed
41988088Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheff)2026https://conductscience.org/library/papers/41988088PubMed
41963297Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal Transduct Target Ther2026https://conductscience.org/library/papers/41963297PubMed
41479921Dual checkpoint blockade of PD-1 and Tim-3 by engineered hybrid nanovesicles for enhanced cancer immunotherapy.Front Immunol2025https://conductscience.org/library/papers/41479921PubMed
41423270TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors.J Immunother Cancer2025https://conductscience.org/library/papers/41423270PubMed
41305010Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41305010PubMed
41301839Tumor-Draining Lymph Node-Targeted Electrochemotherapy: A Hypothesis for In Situ Cancer Vaccination.Biomedicines2025https://conductscience.org/library/papers/41301839PubMed
41249701TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses.Clin Exp Med2025https://conductscience.org/library/papers/41249701PubMed
40631775Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?Oncologist2025https://conductscience.org/library/papers/40631775PubMed
40612954CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.Front Immunol2025https://conductscience.org/library/papers/40612954PubMed
40605058Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40605058PubMed
40561796Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy.Transl Oncol2025https://conductscience.org/library/papers/40561796PubMed

See all 57 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36747017

GET https://conductscience.org/api/papers/v1/36747017/cited_by?page=2